Viruses belong to the class of micro-organisms that are well known for causing infections in the human body. Antiviral medications are given out to prevent the spread of disease-causing viruses. When the viruses are actively reproducing, these agents have their greatest impact. It is particularly challenging to develop virus-specific medications since viruses share the majority of the metabolic functions of the host cell. In the continuous search for better antiviral agents, the United States Food and Drug Administration (USFDA) approved a new drug named Evotaz on January 29, 2015 for the treatment of human immunodeficiency virus (HIV). Evotaz is a combined once-daily fixed drug, containing Atazanavir, an HIV protease inhibitor, and cobicistat, an inhibitor of the human liver cytochrome P450 (CYP) enzyme. The medication is created such that it can kill viruses by concurrently inhibiting protease and CYP enzymes. The medicine is still being studied for a number of criteria, but its usefulness in children under the age of 12 is currently unknown. The preclinical and clinical characteristics of Evotaz, as well as its safety and efficacy profiles and a comparison of the novel drug with antiviral medications presently available in the market, are the main topics of this review paper.

中文翻译：

---

新型HIV-1蛋白酶抑制剂与细胞色素P450（CYP）酶抑制剂的组合探索抗病毒药物的未来前景：Evotaz

病毒属于众所周知会引起人体感染的微生物类别。发放抗病毒药物是为了防止致病病毒的传播。当病毒活跃繁殖时，这些物质的影响最大。开发病毒特异性药物尤其具有挑战性，因为病毒共享宿主细胞的大部分代谢功能。在不断寻找更好的抗病毒药物的过程中，美国食品和药物管理局（USFDA）于2015年1月29日批准了一种名为Evotaz的新药，用于治疗人类免疫缺陷病毒（HIV）。Evotaz 是一种每日一次的组合固定药物，含有阿扎那韦（一种 HIV 蛋白酶抑制剂）和考比司他（一种人肝细胞色素 P450 (CYP) 酶抑制剂）。该药物可以通过同时抑制蛋白酶和 CYP 酶来杀死病毒。该药物的多项标准仍在研究中，但其对 12 岁以下儿童的有效性目前尚不清楚。Evotaz 的临床前和临床特征、其安全性和疗效概况以及该新药与目前市场上可用的抗病毒药物的比较是本综述的主要主题。